Weinstein Kaplan, Bette
March 2013
Oncology Nurse Advisor;Mar/Apr2013, Vol. 4 Issue 2, p35
Product Review
The article offers information about the molecule tyrosine kinase inhibitor, Inlyta or axitinib, from Pfizer including mechanism of action, dosage and administration, and adverse effects.


Related Articles

  • Sorafenib cumulative dose linked to erythrodysaesthesia.  // Reactions Weekly;4/4/2009, Issue 1246, p2 

    The article discusses a study of the role of cumulative sorafenib and bevacizumab doses and anti-vascular endothelial growth factor (VEGF) therapy in increasing the risk of erythrodysaesthesia. The methodology used in the study is described. Findings showed that combination therapy was related...

  • Bevacizumab.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p8 

    The article describes the case of a 51-year-old man with metastatic colorectal cancer who developed papules on his neck 2 months after taking bevacizumab. The lesions were mildly pruritic and showed adherent central keratotic plugs. Her skin biopsy revealed transepidermal collagen elimination...

  • Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome. Lee, Jessica N.; Solimando, Jr., Dominic A.; Waddell, J. Aubrey // Hospital Pharmacy;Jan2013, Vol. 48 Issue 1, p14 

    The article discusses the proper preparation, dispensing and administration of the chemotherapy drugs Ziv-aflibercept and Vincristine Sulfate Liposome and discusses the mechanisms by which the two drugs act and their pharmacokinetics. Possible drug interactions and toxicities related to the two...

  • Short term intraocular pressure changes after intravitreal Bevacizumab injection. Dehghani, Ali; Jafari, Habib; Shoeibi, Naser // Reviews in Clinical Medicine;2014, Vol. 1 Issue 3, p13 

    Intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) have become more popular quickly in recent years. Bevacizumab is an anti- vascular endothelial growth factor agent (anti-VEGF) used to treat choroidal neovascularization and retinal vascular disorders. Rare long...

  • Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante Joseph; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.; Kha Le; Maia, Mauricio; Visich2, Jennifer E. // British Journal of Ophthalmology;Dec2014, Vol. 98 Issue 12, p1636 

    Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking. Methods Fifty-six patients with wet age-related macular degeneration received intravitreal...

  • Axitinib: A Review in Advanced Renal Cell Carcinoma. Keating, Gillian // Drugs;Nov2015, Vol. 75 Issue 16, p1903 

    Axitinib (Inlyta) is a potent, selective inhibitor of vascular endothelial growth factor receptor-1, -2 and -3. This article reviews the clinical efficacy and tolerability of axitinib in patients with previously-treated advanced renal cell carcinoma (RCC), as well as summarizing its...

  • Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. Bhandarkar, Sulochana S.; Jaconi, Marisa; Fried, Levi E.; Bonner, Michael Y.; Lefkove, Benjamin; Govindarajan, Baskaran; Perry, Betsy N.; Parhar, Ravi; Mackelfresh, Jamie; Sohn, Allie; Stouffs, Michael; Knaus, Ulla; Yancopoulos, George; Reiss, Yvonne; Benest, Andrew V.; Augustin, Hellmut G.; Arbiser, Jack L. // Journal of Clinical Investigation;Aug2009, Vol. 119 Issue 8, p2359 

    Hemangiomas are the most common type of tumor in infants. As they are endothelial cell-derived neoplasias, their growth can be regulated by the autocrine-acting Tie2 ligand angiopoietin 2 (Ang2). Using an experimental model of human hemangiomas, in which polyoma middle T-transformed brain...

  • Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial.  // BioWorld Today;9/14/2009, Vol. 20 Issue 176, p1 

    This article reports on the decision of Regeneron Pharmaceuticals Inc. and partner Sanofi-aventis Group to discontinue their Phase III trial of aflibercept plus gemcitabine versus placebo plus gemcitabine for the first-line therapy of metastatic pancreatic cancer. According to an independent...

  • Axitinib. Yang, Lily P.h.; Mckeage, Kate // Drugs;2012, Vol. 72 Issue 18, p2375 

    Axitinib is a new inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3, with greater inhibition potency than existing VEGF receptor inhibitors sunitinib, sorafenib and pazopanib. In a pivotal phase III trial in patients with advanced renal cell carcinoma that had progressed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics